Short and Long-Term Variations in Serum Calciotropic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the Elderly

Romagnoli, Elisabetta; Mascia, Maria Lucia; Cipriani, Cristiana; Fassino, Valeria; Mazzei, Franco; D'Erasmo, E; Carnevale, Vincenzo; Scillitani, Alfredo; Minisola, Salvatore

doi:10.1210/jc.2008-0350

Cited by 288 publications

(239 citation statements)

References 38 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…As regards the literature cited by Dr Roth, the report by Armas et al (2004) was a study of serum 25-hydroxyvitamin D (25(OH)D) till only 1 month after vitamin D dosing, but not longer. The study by Ilahi et al (2008) (and also by Romagnoli et al, 2008) is useful to illustrate the pharmacokinetics of 25(OH)D after administration of a single oral large dose of vitamin D3, and we agree with their suggestion that the levels of 25(OH)D are maintained above baseline for a little beyond 2 months after an oral dose. These results were published only when our study was almost complete.…”

Section: Conflict Of Interestsupporting

confidence: 79%

Response to letter to the editor 2009EJCN0381 (Roth)

et al. 2010

View full text Add to dashboard Cite

average 25-hydroxyvitamin D (25(OH)D) concentration rises to a peak within 2 weeks, then gradually declines towards the baseline concentration over a period of about 2 months (Armas et al., 2004;Ilahi et al., 2008). The single dose of 60 000 IU D3 administered by Sahu et al. in the 5th month of gestation would not be expected to have a perceptible effect on 25(OH)D concentrations in most women at delivery, which was the only time at which the biochemical response was assessed. Even the larger doses administered later in pregnancy would have been predicted to have minor effects on the 25(OH)D concentration measured at delivery, despite almost certainly having caused important but undetected elevations in 25(OH)D concentration during the third trimester. Therefore, it is incorrect to conclude from Sahu et al.'s report that the reported supplement regimens had little or no effect on vitamin D status during pregnancy.The interpretation of the data is further complicated by the unspecified variation in the precise length of the interval between D3 dosing and 25 ( Conflict of interestThe author declares no conflict of interest. Vitamin D replacement in pregnant women in rural north India: a pilot study. DE Roth

show abstract

Section: Conflict Of Interestsupporting

confidence: 79%

Response to letter to the editor 2009EJCN0381 (Roth)

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Ish-Shalom et al 45 documented a rise in both serum 25(OH)D and 1,25(OH)2D concentrations 1 day following a single dose of 1.125 mg of vitamin D3, but these changes were not accompanied by a rise in serum [Ca]. Ilahi et al 46 found that serum [Ca] did not rise in the first 5 days following a single vitamin D3 dose of 2.5 mg, and Romagnoli et al 47 likewise did not find any increase in serum [Ca] after administering 7.5 mg (E Romagnoli, personal communication). However, Cipriani et al 48 recently reported that a single bolus vitamin D3 dose of 15 mg in young adults induced a significant increase in the mean serum calcium concentration on day 3, coincident with a peak mean 1,25(OH)2D concentration.…”

Section: -Hydroxyvitamin D ([25(oh)d]mentioning

confidence: 99%

Vitamin D supplementation during pregnancy: safety considerations in the design and interpretation of clinical trials

Roth

2011

J Perinatol

View full text Add to dashboard Cite

Maternal-child health benefits of optimizing vitamin D status during pregnancy may include a reduced risk of pre-eclampsia, improved fetal growth and beneficial effects on infant immune function. These hypotheses require evaluation by randomized controlled antenatal vitamin D supplementation trials using doses that are high enough to elevate serum 25-hydroxyvitamin D concentrations into the range believed to be associated with improved health outcomes. Such doses may be considerably higher than the current recommended dietary allowance (600 IU day -1 ) or standard prenatal supplement dose (400 IU day -1 ), and may even be higher than the tolerable upper intake level (4000 IU day -1 ) advised by the Institute of Medicine (2010). A critical review of the published literature yielded limited data regarding the safety of antenatal vitamin D regimens. There have been no published reports of the teratogenic effects of vitamin D on humans. Some animal studies have suggested the potential for dosedependent fetal toxicities (for example, growth impairment, skeletal malformations and cardiovascular anomalies), but the relevance of these observations to humans is unknown. Antenatal vitamin D supplementation trials should incorporate a range of methods for objectively establishing maternal and fetal safety, and aim to identify the lowest doses of vitamin D required to achieve target outcomes.

show abstract

“…Nous nous basons pour cela sur des études qui ont montré que, pour une même dose administrée, la vitamine D 3 permettait de maintenir la 25OHD élevée plus longtemps que la vitamine D2 [90][91][92]. Nous devons toutefois signaler que cela n'a pas été retrouvé par toutes les équipes [93].…”

Section: éTapeunclassified

La vitamine D : effets « classiques », « non classiques » et évaluation du statut du patient

Cavalier

Souberbielle

2009

Médecine Nucléaire

View full text Add to dashboard Cite

RésuméLes connaissances sur la vitamine D ont beaucoup progressé ces dernières années. La vitamine D ne peut plus être considérée comme uniquement nécessaire à la prévention du rachitisme/ostéomalacie. Son rôle dans la prévention des fractures ostéoporotiques périphériques du sujet âgé est maintenant bien démontré (en association avec du calcium) et de très nombreuses données épidémiologiques et expérimentales sont en AbstractKnowledge about vitamin D has greatly improved during the last few years. Vitamin D cannot any more be considered as exclusively necessary to prevent ricket/osteomalacia. Its role in the prevention of some osteoporotic fractures in the elderly (in association with calcium nutrition) is now well-demonstrated and many epidemiologic and laboratory data argue for a role in the prevention of several diseases or anomalies (cancer, autoimmune diseases, cardiovascular events, sarcopenia. . .). A few intervention studies confirming some of these effects also exist. Vitamin D status can easily be assessed by measuring serum 25-OH vitamin D level. However, many experts have claimed that the population-based reference values for 25OHD are too low and that the cut-off value below which vitamin D insufficiency can be present is somewhere between 20 and 40 ng/mL with a clear tendency to target values above 30 ng/mL (75 nmol/L). The main consequences are that vitamin D insufficiency is highly frequent whereas the currently recommended supplementation doses are not sufficient. #

show abstract

Short and Long-Term Variations in Serum Calciotropic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the Elderly

Abstract: Cholecalciferol is almost twice as potent as ergocalciferol in increasing serum 25(OH)D, when administered either by mouth or im. 25(OH)D plays a role in modulating serum PTH.

Cited by 288 publications

References 38 publications

Response to letter to the editor 2009EJCN0381 (Roth)

Response to letter to the editor 2009EJCN0381 (Roth)

Vitamin D supplementation during pregnancy: safety considerations in the design and interpretation of clinical trials

La vitamine D : effets « classiques », « non classiques » et évaluation du statut du patient

Contact Info

Product

Resources

About